_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
502804122,7/13/2014 10:57:47,,1321825259,7/13/2014 10:57:40,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804122,7/13/2014 11:07:18,,1321828689,7/13/2014 11:07:02,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804122,7/13/2014 11:50:46,,1321846243,7/13/2014 11:50:34,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,WOLFRAM SYNDROME causes DIABETES INSIPIDUS,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804122,7/13/2014 12:00:27,,1321850017,7/13/2014 11:59:56,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804122,7/13/2014 12:11:38,,1321853857,7/13/2014 12:11:18,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804122,7/13/2014 12:15:08,,1321855011,7/13/2014 12:14:44,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,WOLFRAM SYNDROME causes DIABETES INSIPIDUS,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804122,7/13/2014 12:32:06,,1321861831,7/13/2014 12:31:07,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,85,0,,102,15,causes,0.9950371902,906382-FS1-4,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME,RO-has_manifestation
502804123,7/13/2014 11:07:39,,1321828842,7/13/2014 11:07:20,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,WT BONE causes RICKETS,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804123,7/13/2014 11:49:35,,1321845847,7/13/2014 11:49:17,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,WT BONE causes RICKETS,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804123,7/13/2014 11:50:33,,1321846123,7/13/2014 11:50:19,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,WT BONE causes RICKETS,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804123,7/13/2014 12:10:03,,1321853425,7/13/2014 12:09:25,prodege,0.3,27934334,GBR,E4,Loughton,86.162.38.12,no_relation,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804123,7/13/2014 12:19:54,,1321856847,7/13/2014 12:19:12,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804123,7/13/2014 12:32:42,,1321862044,7/13/2014 12:32:14,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,WT BONE causes RICKETS,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804123,7/13/2014 13:14:14,,1321879000,7/13/2014 13:13:35,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,WT BONE causes RICKETS,0,42,,6,48,causes,0.9950371902,902183-FS1-4,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS,RO-disease_has_primary_anatomic_site
502804124,7/13/2014 11:17:56,,1321833504,7/13/2014 11:17:20,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804124,7/13/2014 11:49:16,,1321845691,7/13/2014 11:48:51,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804124,7/13/2014 11:49:37,,1321845853,7/13/2014 11:49:12,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804124,7/13/2014 12:00:27,,1321850016,7/13/2014 11:59:56,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS causes SULFA ALLERGY,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804124,7/13/2014 12:15:31,,1321855085,7/13/2014 12:15:09,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804124,7/13/2014 13:07:14,,1321876162,7/13/2014 13:06:45,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804124,7/13/2014 13:18:38,,1321880772,7/13/2014 13:18:11,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,SULFA ALLERGY causes DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,371,438,,419,450,causes,0.9370425713,900184-FS1-4,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY,RO-cause_of
502804125,7/13/2014 11:04:00,,1321827552,7/13/2014 11:02:51,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,no_relation,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804125,7/13/2014 11:21:31,,1321835028,7/13/2014 11:20:19,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,PATHOLOGICAL LUNG HALLMARK causes DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804125,7/13/2014 11:59:17,,1321849565,7/13/2014 11:58:43,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT causes PATHOLOGICAL LUNG HALLMARK,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804125,7/13/2014 12:07:33,,1321852534,7/13/2014 12:07:18,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT causes PATHOLOGICAL LUNG HALLMARK,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804125,7/13/2014 12:18:06,,1321856109,7/13/2014 12:17:14,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804125,7/13/2014 12:30:46,,1321861171,7/13/2014 12:29:49,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,no_relation,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804125,7/13/2014 12:43:33,,1321866576,7/13/2014 12:43:09,neodev,0.6177,18517457,GBR,"","",86.29.147.112,no_relation,106,18,,131,73,causes,0.8846517369,902241-FS1-4,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT,RO-disease_has_primary_anatomic_site
502804126,7/13/2014 11:06:47,,1321828499,7/13/2014 11:06:10,neodev,0.5,11014534,GBR,B8,West Wickham,86.18.149.6,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804126,7/13/2014 11:17:14,,1321833122,7/13/2014 11:16:31,neodev,0.9167,28336203,USA,PA,Harrisburg,50.149.53.150,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804126,7/13/2014 11:50:33,,1321846122,7/13/2014 11:50:13,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804126,7/13/2014 11:57:27,,1321848775,7/13/2014 11:57:04,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804126,7/13/2014 12:14:05,,1321854697,7/13/2014 12:13:15,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804126,7/13/2014 12:19:54,,1321856844,7/13/2014 12:19:12,instagc,0.6246,13763729,USA,"","",75.182.89.225,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804126,7/13/2014 12:42:44,,1321866201,7/13/2014 12:42:25,neodev,0.6177,18517457,GBR,"","",86.29.147.112,BONE is location of OSTEOPOROSIS,97,157,,100,168,is location of,0.7453559925,905499-FS1-9,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 11:04:00,,1321827555,7/13/2014 11:02:51,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,OSTEOPOROSIS diagnose_by_test_or_drug BONE,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 11:22:22,,1321835312,7/13/2014 11:21:36,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,OSTEOPOROSIS diagnose_by_test_or_drug BONE,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 11:50:02,,1321845955,7/13/2014 11:49:38,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 11:51:28,,1321846460,7/13/2014 11:51:10,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 11:59:54,,1321849841,7/13/2014 11:59:18,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,BONE diagnose_by_test_or_drug OSTEOPOROSIS,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 12:07:03,,1321852327,7/13/2014 12:06:32,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,OSTEOPOROSIS diagnose_by_test_or_drug BONE,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804127,7/13/2014 12:15:08,,1321855003,7/13/2014 12:14:44,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,BONE diagnose_by_test_or_drug OSTEOPOROSIS,97,157,,100,168,diagnose_by_test_or_drug,0.4472135955,905499-FS1-13,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS,RO-has_finding_site
502804128,7/13/2014 10:58:10,,1321825436,7/13/2014 10:58:03,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,MYXEDEMA treats INTRAVENOUS L THYROXINE,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804128,7/13/2014 11:07:18,,1321828690,7/13/2014 11:07:02,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,INTRAVENOUS L THYROXINE treats MYXEDEMA,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804128,7/13/2014 11:17:56,,1321833494,7/13/2014 11:17:20,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,INTRAVENOUS L THYROXINE treats MYXEDEMA,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804128,7/13/2014 12:07:17,,1321852399,7/13/2014 12:07:04,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,INTRAVENOUS L THYROXINE treats MYXEDEMA,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804128,7/13/2014 13:05:44,,1321875518,7/13/2014 13:05:20,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,INTRAVENOUS L THYROXINE treats MYXEDEMA,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804128,7/13/2014 13:18:26,,1321880665,7/13/2014 13:17:45,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,INTRAVENOUS L THYROXINE treats MYXEDEMA,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804128,7/13/2014 13:18:58,,1321880914,7/13/2014 13:18:39,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,INTRAVENOUS L THYROXINE treats MYXEDEMA,79,106,,86,128,treats,0.9525793444,907952-FS1-2,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE,RO-may_treat
502804129,7/13/2014 11:50:13,,1321845995,7/13/2014 11:49:36,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804129,7/13/2014 11:50:46,,1321846242,7/13/2014 11:50:34,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804129,7/13/2014 11:57:27,,1321848774,7/13/2014 11:57:04,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804129,7/13/2014 12:14:43,,1321854869,7/13/2014 12:14:06,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804129,7/13/2014 12:32:40,,1321862038,7/13/2014 12:32:35,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY treats CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804129,7/13/2014 13:06:44,,1321875944,7/13/2014 13:06:09,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,no_relation,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804129,7/13/2014 13:16:37,,1321880031,7/13/2014 13:15:38,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,90,35,,154,84,treats,0.8111071057,907612-FS1-2,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 11:05:06,,1321827914,7/13/2014 11:04:03,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN diagnose_by_test_or_drug TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 11:05:47,,1321828141,7/13/2014 11:05:11,neodev,0.5,11014534,GBR,B8,West Wickham,86.18.149.6,no_relation,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 11:07:39,,1321828841,7/13/2014 11:07:20,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY diagnose_by_test_or_drug CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 12:06:16,,1321852085,7/13/2014 12:05:31,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY diagnose_by_test_or_drug CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 12:32:26,,1321861982,7/13/2014 12:32:15,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,no_relation,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 12:34:24,,1321862794,7/13/2014 12:33:27,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,no_relation,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804130,7/13/2014 13:12:34,,1321878425,7/13/2014 13:11:36,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY diagnose_by_test_or_drug CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,90,35,,154,84,diagnose_by_test_or_drug,0.4866642634,907612-FS1-13,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,RO-may_treat
502804131,7/13/2014 11:50:02,,1321845956,7/13/2014 11:49:38,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804131,7/13/2014 12:31:38,,1321861565,7/13/2014 12:30:48,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,EPILEPSIES causes SEIZURES,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804131,7/13/2014 13:05:20,,1321875375,7/13/2014 13:04:46,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,EPILEPSIES causes SEIZURES,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804131,7/13/2014 13:20:06,,1321881376,7/13/2014 13:19:49,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,EPILEPSIES causes SEIZURES,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804131,7/13/2014 13:23:45,,1321882852,7/13/2014 13:23:37,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,SEIZURES causes EPILEPSIES,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804131,7/13/2014 13:32:50,,1321886437,7/13/2014 13:32:18,clixsense,0.4762,6500439,AUS,02,Ingleburn,115.146.65.99,SEIZURES causes EPILEPSIES,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804131,7/13/2014 13:33:44,,1321886854,7/13/2014 13:32:44,clixsense,0.25,11764504,GBR,M5,Southend-on-sea,92.232.81.238,no_relation,317,251,,324,260,causes,0.6666666667,904884-FS1-4,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES,RO-has_definitional_manifestation
502804132,7/13/2014 11:44:07,,1321843829,7/13/2014 11:43:26,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804132,7/13/2014 11:50:33,,1321846121,7/13/2014 11:50:13,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804132,7/13/2014 12:07:33,,1321852533,7/13/2014 12:07:18,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804132,7/13/2014 12:19:12,,1321856573,7/13/2014 12:18:49,instagc,0.6246,13763729,USA,"","",75.182.89.225,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804132,7/13/2014 12:42:23,,1321866091,7/13/2014 12:42:00,neodev,0.6177,18517457,GBR,"","",86.29.147.112,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804132,7/13/2014 13:08:03,,1321876611,7/13/2014 13:07:15,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,SEGMENTAL DEFECTS IN BONES causes CONGENITAL MALFORMATION OR NON UNION FRACTURES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804132,7/13/2014 13:16:37,,1321880032,7/13/2014 13:15:38,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,CONGENITAL MALFORMATION OR NON UNION FRACTURES causes SEGMENTAL DEFECTS IN BONES,6,80,,31,125,causes,0.9878783399,905335-FS1-4,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES,RO-has_finding_site
502804133,7/13/2014 11:01:41,,1321826517,7/13/2014 11:00:33,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,LEGIONELLA INFECTION treats LEGIONELLA,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804133,7/13/2014 11:19:31,,1321834131,7/13/2014 11:18:45,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,no_relation,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804133,7/13/2014 12:32:26,,1321861979,7/13/2014 12:32:15,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,no_relation,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804133,7/13/2014 12:42:44,,1321866195,7/13/2014 12:42:25,neodev,0.6177,18517457,GBR,"","",86.29.147.112,no_relation,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804133,7/13/2014 13:06:44,,1321875943,7/13/2014 13:06:09,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,no_relation,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804133,7/13/2014 13:15:36,,1321879470,7/13/2014 13:14:59,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,LEGIONELLA INFECTION treats LEGIONELLA,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804133,7/13/2014 13:23:45,,1321882853,7/13/2014 13:23:37,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,LEGIONELLA treats LEGIONELLA INFECTION,47,47,,56,66,treats,0.6708203932,903796-FS1-2,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION,RO-has_causative_agent
502804134,7/13/2014 10:57:55,,1321825338,7/13/2014 10:57:48,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,HAEMOPHILIA A causes VIII (FVIII) GENE,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804134,7/13/2014 11:06:09,,1321828292,7/13/2014 11:05:48,neodev,0.5,11014534,GBR,B8,West Wickham,86.18.149.6,VIII (FVIII) GENE causes HAEMOPHILIA A,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804134,7/13/2014 11:44:43,,1321844006,7/13/2014 11:44:08,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,VIII (FVIII) GENE causes HAEMOPHILIA A,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804134,7/13/2014 12:32:34,,1321862010,7/13/2014 12:32:27,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,VIII (FVIII) GENE causes HAEMOPHILIA A,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804134,7/13/2014 13:14:58,,1321879264,7/13/2014 13:14:16,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,VIII (FVIII) GENE causes HAEMOPHILIA A,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804134,7/13/2014 13:18:58,,1321880913,7/13/2014 13:18:39,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,VIII (FVIII) GENE causes HAEMOPHILIA A,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804134,7/13/2014 13:19:48,,1321881260,7/13/2014 13:19:05,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,VIII (FVIII) GENE causes HAEMOPHILIA A,25,134,,37,150,causes,0.9918365981,906205-FS1-4,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE,RO-has_manifestation
502804135,7/13/2014 11:02:47,,1321827062,7/13/2014 11:01:45,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804135,7/13/2014 11:07:01,,1321828530,7/13/2014 11:06:35,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,DISTINCTIVE SKIN LESIONS causes EPIDERMAL NEVUS SYNDROME,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804135,7/13/2014 11:46:02,,1321844648,7/13/2014 11:45:22,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804135,7/13/2014 12:07:43,,1321852558,7/13/2014 12:06:57,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,DISTINCTIVE SKIN LESIONS causes EPIDERMAL NEVUS SYNDROME,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804135,7/13/2014 12:10:03,,1321853432,7/13/2014 12:09:25,prodege,0.3,27934334,GBR,E4,Loughton,86.162.38.12,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804135,7/13/2014 12:42:23,,1321866092,7/13/2014 12:42:00,neodev,0.6177,18517457,GBR,"","",86.29.147.112,no_relation,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804135,7/13/2014 13:06:08,,1321875724,7/13/2014 13:05:45,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,EPIDERMAL NEVUS SYNDROME causes DISTINCTIVE SKIN LESIONS,75,4,,98,27,causes,0.9761870602,905337-FS1-4,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME,RO-has_finding_site
502804136,7/13/2014 10:58:02,,1321825357,7/13/2014 10:57:55,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,TUBERCULOSIS diagnose_by_test_or_drug N PURIFIED PROTEIN DERIVATIV,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804136,7/13/2014 11:07:01,,1321828528,7/13/2014 11:06:35,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,TUBERCULOSIS diagnose_by_test_or_drug N PURIFIED PROTEIN DERIVATIV,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804136,7/13/2014 11:20:13,,1321834501,7/13/2014 11:19:35,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,TUBERCULOSIS diagnose_by_test_or_drug N PURIFIED PROTEIN DERIVATIV,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804136,7/13/2014 11:46:40,,1321844834,7/13/2014 11:46:03,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,N PURIFIED PROTEIN DERIVATIV diagnose_by_test_or_drug TUBERCULOSIS,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804136,7/13/2014 11:49:16,,1321845692,7/13/2014 11:48:51,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804136,7/13/2014 12:06:16,,1321852084,7/13/2014 12:05:31,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,no_relation,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804136,7/13/2014 12:32:13,,1321861864,7/13/2014 12:32:08,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,N PURIFIED PROTEIN DERIVATIV diagnose_by_test_or_drug TUBERCULOSIS,31,101,,42,128,diagnose_by_test_or_drug,0.9615239476,906547-FS1-13,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV,RO-may_diagnose
502804137,7/13/2014 11:06:34,,1321828444,7/13/2014 11:06:23,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,SPONDYLOARTHROPATHIES causes ANKYLOSING SPONDYLITIS,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804137,7/13/2014 11:50:18,,1321846034,7/13/2014 11:50:11,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804137,7/13/2014 12:07:49,,1321852583,7/13/2014 12:07:33,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804137,7/13/2014 12:13:54,,1321854649,7/13/2014 12:12:47,sendearnings,0.3333,11896941,USA,FL,Seminole,97.106.105.251,SPONDYLOARTHROPATHIES causes ANKYLOSING SPONDYLITIS,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804137,7/13/2014 12:18:25,,1321856235,7/13/2014 12:18:07,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804137,7/13/2014 13:07:14,,1321876161,7/13/2014 13:06:45,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,ANKYLOSING SPONDYLITIS causes SPONDYLOARTHROPATHIES,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804137,7/13/2014 13:18:38,,1321880773,7/13/2014 13:18:11,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,94,58,,115,78,causes,0.8333333333,906306-FS1-4,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,RO-has_manifestation
502804138,7/13/2014 10:58:10,,1321825437,7/13/2014 10:58:03,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,MYASTHENIA GRAVIS treats (EDROPHONIUM CHLORIDE),178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804138,7/13/2014 11:01:41,,1321826515,7/13/2014 11:00:33,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804138,7/13/2014 11:17:14,,1321833123,7/13/2014 11:16:31,neodev,0.9167,28336203,USA,PA,Harrisburg,50.149.53.150,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804138,7/13/2014 11:46:02,,1321844649,7/13/2014 11:45:22,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804138,7/13/2014 11:58:42,,1321849300,7/13/2014 11:57:59,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804138,7/13/2014 12:32:06,,1321861811,7/13/2014 12:31:07,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,MYASTHENIA GRAVIS treats (EDROPHONIUM CHLORIDE),178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804138,7/13/2014 13:18:09,,1321880580,7/13/2014 13:17:17,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,(EDROPHONIUM CHLORIDE) treats MYASTHENIA GRAVIS,178,122,,194,143,treats,0.9761870602,906603-FS1-2,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE),RO-may_diagnose
502804139,7/13/2014 11:06:22,,1321828378,7/13/2014 11:06:09,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,ALLERGIC REACTIONS causes ALLERGIES TO BEE AND,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804139,7/13/2014 12:16:01,,1321855288,7/13/2014 12:15:33,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,ALLERGIES TO BEE AND causes ALLERGIC REACTIONS,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804139,7/13/2014 12:20:15,,1321856961,7/13/2014 12:19:55,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804139,7/13/2014 12:32:13,,1321861862,7/13/2014 12:31:39,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,no_relation,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804139,7/13/2014 13:19:48,,1321881279,7/13/2014 13:19:30,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,ALLERGIES TO BEE AND causes ALLERGIC REACTIONS,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804139,7/13/2014 13:23:53,,1321882933,7/13/2014 13:23:46,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,ALLERGIC REACTIONS causes ALLERGIES TO BEE AND,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804139,7/13/2014 13:33:44,,1321886855,7/13/2014 13:32:44,clixsense,0.25,11764504,GBR,M5,Southend-on-sea,92.232.81.238,ALLERGIC REACTIONS causes ALLERGIES TO BEE AND,40,121,,57,140,causes,0.4,900125-FS1-4,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND,RO-cause_of
502804140,7/13/2014 10:58:02,,1321825377,7/13/2014 10:57:55,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,MYELOFIBROSIS causes ACUTE MEGAKARYOCYTIC MYELOSIS,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804140,7/13/2014 11:19:31,,1321834132,7/13/2014 11:18:45,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,no_relation,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804140,7/13/2014 11:57:58,,1321849002,7/13/2014 11:57:29,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804140,7/13/2014 12:06:57,,1321852276,7/13/2014 12:06:18,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,no_relation,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804140,7/13/2014 12:14:05,,1321854694,7/13/2014 12:13:15,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,MYELOFIBROSIS causes ACUTE MEGAKARYOCYTIC MYELOSIS,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804140,7/13/2014 12:18:06,,1321856106,7/13/2014 12:17:14,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804140,7/13/2014 12:30:46,,1321861169,7/13/2014 12:29:49,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,MYELOFIBROSIS causes ACUTE MEGAKARYOCYTIC MYELOSIS,136,170,,148,198,causes,0.3849001795,902524-FS1-4,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS,RO-disease_may_have_finding
502804141,7/13/2014 11:00:30,,1321826032,7/13/2014 10:59:48,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804141,7/13/2014 11:50:11,,1321845988,7/13/2014 11:50:03,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804141,7/13/2014 12:32:40,,1321862039,7/13/2014 12:32:35,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804141,7/13/2014 13:13:33,,1321878812,7/13/2014 13:12:36,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,no_relation,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804141,7/13/2014 13:19:48,,1321881262,7/13/2014 13:19:05,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804141,7/13/2014 13:23:36,,1321882828,7/13/2014 13:23:29,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804141,7/13/2014 13:33:11,,1321886537,7/13/2014 13:32:50,clixsense,0.4762,6500439,AUS,02,Ingleburn,115.146.65.99,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,122,190,,131,202,diagnose_by_test_or_drug,0.9958932065,906529-FS1-13,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 10:57:39,,1321825203,7/13/2014 10:56:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 11:21:31,,1321835079,7/13/2014 11:20:19,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 12:15:31,,1321855087,7/13/2014 12:15:09,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,DEXAMETHASONE diagnose_by_test_or_drug DEPRESSION,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 12:32:42,,1321862046,7/13/2014 12:32:14,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,DEXAMETHASONE diagnose_by_test_or_drug DEPRESSION,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 12:32:47,,1321862063,7/13/2014 12:32:41,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 13:20:06,,1321881379,7/13/2014 13:19:49,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804142,7/13/2014 13:23:36,,1321882803,7/13/2014 13:23:29,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,DEXAMETHASONE diagnose_by_test_or_drug DEPRESSION,82,4,,91,16,diagnose_by_test_or_drug,0.990147543,906827-FS1-13,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE,RO-may_diagnose
502804143,7/13/2014 10:59:47,,1321825859,7/13/2014 10:59:22,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,PHAEOCHROMOCYTOMA causes HYPERTENSION,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804143,7/13/2014 11:18:38,,1321833729,7/13/2014 11:18:01,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,HYPERTENSION causes PHAEOCHROMOCYTOMA,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804143,7/13/2014 11:51:28,,1321846461,7/13/2014 11:51:10,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804143,7/13/2014 11:59:17,,1321849564,7/13/2014 11:58:43,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804143,7/13/2014 12:07:17,,1321852410,7/13/2014 12:07:04,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,PHAEOCHROMOCYTOMA causes HYPERTENSION,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804143,7/13/2014 12:07:43,,1321852554,7/13/2014 12:06:57,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,HYPERTENSION causes PHAEOCHROMOCYTOMA,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804143,7/13/2014 12:18:49,,1321856432,7/13/2014 12:18:25,instagc,0.6246,13763729,USA,"","",75.182.89.225,PHAEOCHROMOCYTOMA causes HYPERTENSION,31,103,,42,119,causes,0.894427191,902902-FS1-4,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA,RO-disease_may_have_finding
502804144,7/13/2014 12:11:38,,1321853856,7/13/2014 12:11:18,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804144,7/13/2014 12:13:13,,1321854324,7/13/2014 12:12:17,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,HEPATOMA causes HEPATOMEGALY,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804144,7/13/2014 12:13:54,,1321854642,7/13/2014 12:12:47,sendearnings,0.3333,11896941,USA,FL,Seminole,97.106.105.251,HEPATOMEGALY causes HEPATOMA,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804144,7/13/2014 12:18:25,,1321856232,7/13/2014 12:18:07,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804144,7/13/2014 12:41:27,,1321865772,7/13/2014 12:40:38,neodev,0.6177,18517457,GBR,"","",86.29.147.112,no_relation,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804144,7/13/2014 13:19:48,,1321881278,7/13/2014 13:19:30,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804144,7/13/2014 13:21:13,,1321881838,7/13/2014 13:20:41,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,52,23,,63,30,causes,0.914991422,902609-FS1-4,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA,RO-disease_may_have_finding
502804145,7/13/2014 11:18:38,,1321833728,7/13/2014 11:18:01,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,no_relation,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804145,7/13/2014 12:08:03,,1321852686,7/13/2014 12:07:50,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804145,7/13/2014 12:13:13,,1321854322,7/13/2014 12:12:17,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804145,7/13/2014 12:33:27,,1321862376,7/13/2014 12:32:43,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804145,7/13/2014 12:41:59,,1321865962,7/13/2014 12:41:29,neodev,0.6177,18517457,GBR,"","",86.29.147.112,no_relation,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804145,7/13/2014 13:08:03,,1321876609,7/13/2014 13:07:15,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,no_relation,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804145,7/13/2014 13:18:26,,1321880670,7/13/2014 13:17:45,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,132,41,,191,82,treats,0.4,908111-FS1-2,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A,RO-may_treat
502804146,7/13/2014 11:06:09,,1321828290,7/13/2014 11:05:47,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804146,7/13/2014 11:50:33,,1321846124,7/13/2014 11:50:19,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804146,7/13/2014 12:16:01,,1321855289,7/13/2014 12:15:33,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804146,7/13/2014 13:05:20,,1321875374,7/13/2014 13:04:46,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804146,7/13/2014 13:12:34,,1321878421,7/13/2014 13:11:36,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804146,7/13/2014 13:16:24,,1321879908,7/13/2014 13:15:20,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804146,7/13/2014 13:19:29,,1321881117,7/13/2014 13:18:59,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,75,39,,121,49,treats,0.9701425001,907641-FS1-2,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE,RO-may_treat
502804147,7/13/2014 11:17:37,,1321833305,7/13/2014 11:17:15,neodev,0.9167,28336203,USA,PA,Harrisburg,50.149.53.150,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804147,7/13/2014 11:45:22,,1321844341,7/13/2014 11:44:44,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804147,7/13/2014 11:49:35,,1321845852,7/13/2014 11:49:17,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804147,7/13/2014 12:20:15,,1321856963,7/13/2014 12:19:55,instagc,0.6246,13763729,USA,"","",75.182.89.225,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804147,7/13/2014 13:06:08,,1321875726,7/13/2014 13:05:45,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804147,7/13/2014 13:15:36,,1321879469,7/13/2014 13:14:59,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804147,7/13/2014 13:21:13,,1321881839,7/13/2014 13:20:41,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,METHOTREXATE treats OSTEOSARCOMA,114,142,,125,153,treats,0.9759000729,908313-FS1-2,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE,RO-may_treat
502804148,7/13/2014 10:57:55,,1321825340,7/13/2014 10:57:48,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,TESTES is location of SPERMATOGENIC ARREST,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804148,7/13/2014 11:05:47,,1321828133,7/13/2014 11:05:11,neodev,0.5,11014534,GBR,B8,West Wickham,86.18.149.6,no_relation,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804148,7/13/2014 12:04:04,,1321851280,7/13/2014 12:03:14,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,TESTES is location of SPERMATOGENIC ARREST,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804148,7/13/2014 12:34:24,,1321862768,7/13/2014 12:33:27,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,no_relation,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804148,7/13/2014 12:41:27,,1321865774,7/13/2014 12:40:38,neodev,0.6177,18517457,GBR,"","",86.29.147.112,TESTES is location of SPERMATOGENIC ARREST,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804148,7/13/2014 13:13:33,,1321878811,7/13/2014 13:12:36,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,TESTES is location of SPERMATOGENIC ARREST,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804148,7/13/2014 13:20:40,,1321881628,7/13/2014 13:19:49,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,112,204,,117,223,is location of,0.7844645406,905466-FS1-9,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST,RO-has_finding_site
502804149,7/13/2014 10:58:17,,1321825480,7/13/2014 10:58:11,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION treats AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804149,7/13/2014 11:06:22,,1321828372,7/13/2014 11:06:09,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,no_relation,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804149,7/13/2014 11:06:47,,1321828503,7/13/2014 11:06:10,neodev,0.5,11014534,GBR,B8,West Wickham,86.18.149.6,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804149,7/13/2014 11:45:22,,1321844339,7/13/2014 11:44:44,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804149,7/13/2014 11:50:11,,1321845987,7/13/2014 11:50:03,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804149,7/13/2014 12:05:30,,1321851814,7/13/2014 12:04:42,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804149,7/13/2014 12:14:43,,1321854862,7/13/2014 12:14:06,clixsense,0.5603,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,126,39,,171,83,treats,0.7302967433,907304-FS1-2,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 11:06:09,,1321828291,7/13/2014 11:05:48,neodev,0.5,11014534,GBR,B8,West Wickham,86.18.149.6,no_relation,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 11:06:34,,1321828441,7/13/2014 11:06:23,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN causes INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 11:44:07,,1321843828,7/13/2014 11:43:26,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 13:19:29,,1321881127,7/13/2014 13:18:59,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 13:20:40,,1321881634,7/13/2014 13:19:49,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 13:24:01,,1321883005,7/13/2014 13:23:54,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN causes INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804150,7/13/2014 13:32:50,,1321886435,7/13/2014 13:32:18,clixsense,0.4762,6500439,AUS,02,Ingleburn,115.146.65.99,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN causes INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,126,39,,171,83,causes,0.5477225575,907304-FS1-4,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN,RO-may_prevent
502804151,7/13/2014 10:59:47,,1321825858,7/13/2014 10:59:22,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804151,7/13/2014 11:50:13,,1321845994,7/13/2014 11:49:36,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804151,7/13/2014 12:04:40,,1321851463,7/13/2014 12:04:05,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804151,7/13/2014 12:08:03,,1321852718,7/13/2014 12:07:50,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804151,7/13/2014 12:43:33,,1321866575,7/13/2014 12:43:09,neodev,0.6177,18517457,GBR,"","",86.29.147.112,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804151,7/13/2014 13:05:44,,1321875517,7/13/2014 13:05:20,instagc,0.6448,23149109,USA,NC,Durham,75.189.206.205,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804151,7/13/2014 13:14:58,,1321879265,7/13/2014 13:14:16,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,VARIOLA MAJOR VIRUS causes SMALLPOX,0,43,,18,50,causes,1,903785-FS1-4,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX,RO-has_causative_agent
502804152,7/13/2014 11:02:47,,1321827061,7/13/2014 11:01:45,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,no_relation,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804152,7/13/2014 12:05:30,,1321851811,7/13/2014 12:04:42,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,CHRONIC RELAPSING ATOPIC DERMATITIS causes A MODEL OF ATOPIC DISEASE,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804152,7/13/2014 12:07:03,,1321852326,7/13/2014 12:06:32,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,CHRONIC RELAPSING ATOPIC DERMATITIS causes A MODEL OF ATOPIC DISEASE,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804152,7/13/2014 12:18:49,,1321856431,7/13/2014 12:18:25,instagc,0.6246,13763729,USA,"","",75.182.89.225,no_relation,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804152,7/13/2014 12:32:13,,1321861869,7/13/2014 12:31:39,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,A MODEL OF ATOPIC DISEASE causes CHRONIC RELAPSING ATOPIC DERMATITIS,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804152,7/13/2014 12:32:34,,1321862008,7/13/2014 12:32:27,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,A MODEL OF ATOPIC DISEASE causes CHRONIC RELAPSING ATOPIC DERMATITIS,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804152,7/13/2014 12:43:08,,1321866356,7/13/2014 12:42:46,neodev,0.6177,18517457,GBR,"","",86.29.147.112,no_relation,89,48,,123,72,causes,0.8980265101,900111-FS1-4,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE,RO-cause_of
502804153,7/13/2014 10:57:47,,1321825250,7/13/2014 10:57:40,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,TETRACYCLINE contraindicates PREGNANCY,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804153,7/13/2014 11:20:13,,1321834502,7/13/2014 11:19:35,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,no_relation,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804153,7/13/2014 11:44:43,,1321844009,7/13/2014 11:44:08,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804153,7/13/2014 11:51:09,,1321846364,7/13/2014 11:50:34,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,PREGNANCY contraindicates TETRACYCLINE,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804153,7/13/2014 11:58:42,,1321849302,7/13/2014 11:57:59,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804153,7/13/2014 12:04:40,,1321851464,7/13/2014 12:04:05,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,PREGNANCY contraindicates TETRACYCLINE,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804153,7/13/2014 12:31:38,,1321861566,7/13/2014 12:30:48,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,no_relation,399,370,,410,378,contraindicates,0.8219949365,901288-FS1-10,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY,RO-contraindicated_drug
502804154,7/13/2014 11:17:37,,1321833303,7/13/2014 11:17:15,neodev,0.9167,28336203,USA,PA,Harrisburg,50.149.53.150,TUBERCULIN treats 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804154,7/13/2014 11:22:22,,1321835311,7/13/2014 11:21:36,rewardsspot,0.7222,24482174,GBR,H9,London,46.23.68.180,no_relation,34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804154,7/13/2014 11:46:40,,1321844835,7/13/2014 11:46:03,instagc,0.6583,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804154,7/13/2014 11:50:18,,1321846033,7/13/2014 11:50:11,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804154,7/13/2014 11:57:58,,1321849003,7/13/2014 11:57:29,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) treats TUBERCULIN,34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804154,7/13/2014 12:06:57,,1321852274,7/13/2014 12:06:18,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,no_relation,34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804154,7/13/2014 13:19:04,,1321880957,7/13/2014 13:18:28,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,34,124,,76,133,treats,0.6123724357,906978-FS1-2,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN,RO-may_diagnose
502804155,7/13/2014 10:58:17,,1321825481,7/13/2014 10:58:11,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804155,7/13/2014 11:49:37,,1321845855,7/13/2014 11:49:12,prodege,0.5986,12944140,GBR,I4,Mitcham,92.21.66.102,no_relation,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804155,7/13/2014 11:59:54,,1321849842,7/13/2014 11:59:18,prodege,0.4611,28039757,GBR,L8,Southport,109.155.158.54,no_relation,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804155,7/13/2014 12:04:04,,1321851295,7/13/2014 12:03:14,vivatic,0.5236,25451531,GBR,"","",83.67.28.193,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804155,7/13/2014 12:32:13,,1321861871,7/13/2014 12:32:08,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804155,7/13/2014 12:41:59,,1321865963,7/13/2014 12:41:29,neodev,0.6177,18517457,GBR,"","",86.29.147.112,DENTAL FLUOROSIS causes BLOOD FLUORIDE CONCENTRATION,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804155,7/13/2014 13:19:04,,1321880960,7/13/2014 13:18:28,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,BLOOD FLUORIDE CONCENTRATION causes DENTAL FLUOROSIS,17,93,,44,108,causes,0.5570860145,903506-FS1-4,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS,RO-has_causative_agent
502804156,7/13/2014 11:05:06,,1321827912,7/13/2014 11:04:03,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,SYSTEMIC HYPERTENSION treats SUBLINGUAL NIFEDIPINE,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804156,7/13/2014 12:07:49,,1321852586,7/13/2014 12:07:33,instagc,0.6389,15445601,USA,FL,Jacksonville,24.129.68.254,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804156,7/13/2014 12:19:12,,1321856566,7/13/2014 12:18:49,instagc,0.6246,13763729,USA,"","",75.182.89.225,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804156,7/13/2014 12:32:47,,1321862062,7/13/2014 12:32:41,prodege,0.4998,28480832,GBR,J1,Northampton,78.151.200.222,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804156,7/13/2014 12:43:08,,1321866349,7/13/2014 12:42:46,neodev,0.6177,18517457,GBR,"","",86.29.147.112,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804156,7/13/2014 13:14:14,,1321879003,7/13/2014 13:13:35,instagc,0.7056,19686223,CAN,BC,Surrey,154.20.155.106,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804156,7/13/2014 13:23:53,,1321882923,7/13/2014 13:23:46,neodev,0.302,25224036,CAN,ON,Sudbury,67.204.218.187,no_relation,95,47,,115,67,treats,0.9878783399,907907-FS1-2,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE,RO-may_treat
502804157,7/13/2014 10:57:39,,1321825202,7/13/2014 10:56:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
502804157,7/13/2014 11:00:30,,1321826036,7/13/2014 10:59:48,clixsense,0.9167,15189335,GBR,I9,Norwich,86.155.45.231,no_relation,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
502804157,7/13/2014 11:06:09,,1321828289,7/13/2014 11:05:47,clixsense,0.6806,27793793,GBR,C5,Chester,151.230.27.155,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
502804157,7/13/2014 11:51:09,,1321846365,7/13/2014 11:50:34,instagc,0.6486,19004168,GBR,H2,Accrington,80.47.185.52,no_relation,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
502804157,7/13/2014 12:33:27,,1321862384,7/13/2014 12:32:43,clixsense,0.4819,27969116,NLD,04,Veendam,185.12.216.74,ARTERIAL HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
502804157,7/13/2014 13:16:24,,1321879913,7/13/2014 13:15:20,instagc,0.7079,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
502804157,7/13/2014 13:18:09,,1321880581,7/13/2014 13:17:17,neodev,0.6736,14861092,GBR,I2,Manchester,90.194.137.76,HYPERTENSIVE ENCEPHALOPATHY causes ARTERIAL HYPERTENSION,13,45,,33,71,causes,0.9630868247,901903-FS1-4,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,RO-disease_has_finding
